Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study-Reference-Cited by-同舟云学术

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study

Published:2018-10-20 Issue:6 Volume:27 Page:2301-2312
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Ludwig Heinz,Gascón Pere,Bokemeyer Carsten,Aapro Matti,Boccadoro Mario,Denhaerynck Kris,Krendyukov Andriy,MacDonald Karen,Abraham Ivo^ORCID

Funder

HEXAL AG

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-018-4513-6.pdf

Reference20 articles.

1. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearnery N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte- colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32. https://doi.org/10.1016/j.ejca.2010.10.013

2. National Comprehensive Center Network (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloid growth factors version 2.2016. www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf . Accessed 31 Oct 2016

3. Lokich J (2005) Same-day pegfilgrastim and chemotherapy. Cancer Investig 23:573–576. https://doi.org/10.1080/07357900500276899

4. Whitworth JM, Matthews KS, Shipman KA, Numnum TM, Kendrick JE, Kilgore LC, Straughn JM (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112:601–604. https://doi.org/10.1016/j.ygyno.2008.10.025

5. Cheng C, Gallagher EM, Yeh JY, Earl MA (2014) Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab. Anti-Cancer Drugs 25:964–969. https://doi.org/10.1097/CAD.0000000000000115

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Filgrastim biosimilar (EP2006): A review of 15 years’ post-approval evidence;Critical Reviews in Oncology/Hematology;2024-04

2. Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement;Supportive Care in Cancer;2022-11-05

3. Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy;Future Oncology;2022-07

4. Effect of concomitant use of G-CSF and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse model;Medical Oncology;2022-06-06

5. Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer;Future Oncology;2022-06